Search

Displaying results 4031 - 4040 of 10000 in total
  1. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

  2. Drug

    Oxprenolol

    go.drugbank.com/drugs/DB01580
    ApprovedWithdrawn

    A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

  3. Drug

    Pyrethrum extract

    go.drugbank.com/drugs/DB11087
    Approved

    Pyrethrum is the crude extract form obtained from flowers of the plant Chrysanthemum cinerariifolium. Pyrethrin refers to a more refined extract of pyrethrum. … The active compound is absorbed by the lice and destroys them by acting on their nervous systems but is thought to exert minimal effect on humans.

  4. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB. … [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]

  5. Drug

    Roquinimex

    go.drugbank.com/drugs/DB11366
    Experimental

    Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

  6. Drug

    Quinestrol

    go.drugbank.com/drugs/DB04575
    Approved

    The 3-cyclopentyl ether of ethinyl estradiol.

  7. Drug

    Bleomycin

    go.drugbank.com/drugs/DB00290
    ApprovedInvestigational

    Bleomycin A2 is used as the representative structure for Bleomycin.

    Products: Bleomycin Accord 15.000 IE Pulver zur Herstellung einer Injektions-/Infusionslösung
  8. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    of resistance mutations, particularly the solvent front G2032R substitution, and progression of disease in the brain. … Zidesamtinib is an orally administered ROS1 kinase inhibitor designed to remain active against ROS1 resistance mutations.

  9. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    [A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

  10. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    As it is injectable, it can be used perioperatively when patients are unable to take oral medications. … It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx).